Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 23 for “"ER+ breast cancer"”.
-
Proteomic Map of ER+ Breast Cancer Cell Cycle
Cancer is characterized by a deregulation of the cell cycle resulting in abnormal proliferation of cells that can bypass tightly regulated molecular checkpoints. Breast cancer is the most common cancer diagnosed in women, ~70% of cases displaying an estrogen receptor positive (ER+) phenotype. The …
-
The impact of ARID1A loss on ER+ breast cancer: mechanistic insights and therapeutic opportunities
Metastasis is the leading cause of mortality in breast cancer patients. Up to 12 % of all ER+ breast cancer metastases harbour mutations in ARID1A, a critical subunit of the SWI/SNF chromatin remodelling complex. In 2020, Nagarajan et al. have shown that ARID1A mutations contribute to resistance to …
-
Proteomic identification of putative biomarkers of neo-adjuvant chemotherapy resistance in luminal (ER+) breast cancer
Background:Neoadjuvant chemotherapy is a standard treatment for locally advanced breast cancer however chemoresistance can be a major obstacle in ER+ cancers. Using comparative proteomic approaches (antibody microarray/AbMA and 2D-PAGE with MALDI-TOF/TOF MS) to investigate a pilot series of breast …
-
Regulation of the Glucocorticoid Receptor Promoter and Its Prognostic Value in Tamoxifen-Treated ER+ Breast Cancer
Most breast cancers are estrogen receptor positive (ER+) and therefore benefit from endocrine-based therapies such as tamoxifen which impair estrogen signaling. However, resistance is a major clinical concern and ER status alone is insufficient to predict treatment response. As a result, additional …
-
Notch-1 Activates Nf-Кb Activity in Cervical Cancer and Estrogen Receptor Negative Breast Cancer
<p>Breast and cervical cancer are two common cancers that severely endanger women's health. The fatality rates of breast and cervical cancer are ranked first and fifth, respectively, in cancer related deaths in women worldwide. Continuous dedication to cancer research is urgently required to …
-
Aminoflavone Inhibits α6-integrin and Growth of Tamoxifen Resistant Breast Cancer
… 40% of estrogen receptor positive (ER+) breast cancer patients develop resistance to standard of care agent tamoxifen, while ER negative (ER-) breast cancer patients are intrinsically resistant to tamoxifen. Resistance often promotes metastasis, recurrence and death. Tumor-initiating …
-
New molecular approches using AR, FOXA1 and HER2 for outcome classification of estrogen Receptor-Positive (ER+) breast cancers”
Here, we studied new prognostic and predictive easy access strategies in breast cancer (molecular markers), for better classify ER+ breast cancer disease, which might provide additional information and be complementary to the clasical clinical-pathological prediction models.
-
Characterising the role of TET2 in oestrogen receptor positive breast cancer
… the transcription factor oestrogen receptor α (ER) drives tumour development and metastasis in ER positive (ER+) breast cancer. This subtype constitutes up to three-quarters of breast cancer cases, and treatments directly targeting ER are currently the standard of care. ER operates as part of a …
-
The role of metabolic rewiring in endocrine resistance
Breast cancer is the most common cancer type in women population affecting a large number of women worldwide. Due to its highly heterogenous molecular characteristics, there is not a default treatment strategy for breast cancer. Almost two third of breast cancer cases are estrogen receptor positive …
-
An Exploration of the Lives of Young, African American Women with Triple-Negative Breast Cancer
<p>Compared to other subtypes of breast cancer, triple-negative breast cancer: TNBC) accounts for a disproportionate number of metastatic cases and cancer deaths. Glaring disparities are present in the occurrence of TNBC, such that those diagnosed are more likely to be African American: prevalence …
-
Tracing Androgen Metabolism With Inhibition Of Aromatase In Breast Cancer: In Vitro Studies And Clinical Correlates
… of rational drug design in hormone-responsive cancer. Aromatase inhibitors (AI) are approved as a first line of therapy in both primary and metastatic estrogen-receptor positive (ER+) breast cancer, and have been shown to be superior to tamoxifen at preventing local and distant recurrence. In …
-
The G protein-coupled receptor GPR30 signalosome - A novel G protein-independent mechanism regulating cAMP signaling and receptor trafficking
… fact that GPCRs are involved in essentially every physiological event, and that ~50% of drugs on the current market are either directly or indirectly targeted towards the function of GPCRs, we can be certain of their considerable importance. This thesis is dedicated solely to one particular …
-
Vitamin B6 Decreases Proliferation and DNA Synthesis in Human Mammary Carcinoma Cell Lines In Vitro
The growth of many breast cancers is stimulated by the action of the hormone estrogen. Hormonal therapy used to treat these estrogen-dependent breast cancers acts by interfering with the action of estrogen. Current treatments, such as tamoxifen, are not consistently useful due to development of …
-
Epigenetic Regulation of Nuclear Hormone Receptor DAX-1
… key role in the development and maintenance of steroidogenic tissue in mammals. Dax-1 is also expressed in mouse embryonic stem (ES) cells and is required to maintain pluripotency. Duplication of the X-chromosome in the region containing the NR0B1 gene results in sex reversal, and mutations in …
-
The decision making process in women diagnosed with estrogen receptor-positive breast cancer experiencing side effects related to oral endocrine therapy
Oral endocrine therapy (OET) is standard therapy for millions of estrogen receptor-positive breast cancer survivors (ER+BCS). OET reduces recurrence, mortality, and metastasis. ER+BCS often do not take their OET as recommended due to adverse side effects. The purpose of this dissertation was to …
-
The Potential Role of Insulin (and Stress Response) Pathway Components In Breast Cancer Development and Progression
<p>Breast cancer is characterized into several subtypes, which are further classified by the status of three central receptors: estrogen (ER), progesterone (PR), and human epidermal growth factor (Her2/neu). These subtypes differ according to etiology, tumor grade, clinical outcomes, and responses …
-
Resolving Intra-Tumoral Heterogeneity of Breast Cancer Using Single-Cell Multi-Omics
<p>Breast cancer is a highly heterogeneous disease characterized by diverse genetic, transcriptional, and epigenetic landscapes. Understanding how intra-tumoral heterogeneity (ITH) influences therapeutic response and drives tumor evolution remains a central challenge in cancer biology. Here, we …
-
Targeting Autophagy to Improve Efficacy of Cdk4/6 Inhibition In Breast Cancer
<p>Deregulation of the cell cycle machinery is a hallmark of cancer, leading to aberrant proliferation and tumorigenesis. The crucial role of the CDK4/6-Cyclin D pathway has led to the development and FDA approval (palbociclib, ribociclib) of CDK4/6 inhibitors for the treatment of advanced estrogen …
-
Spectroscopic characterization of iron-oxygen intermediates in human aromatase (CYP19A1)
CYP19A1 or aromatase, is a human steroidogenic P450 important for estrogen biosynthesis in humans. Over activation of aromatase results in malignancies of the breast tissue, especially in post menopausal women. In fact, aromatase inhibitors constitute the front line therapy for estrogen receptor …
-
Development of Novel anti-estrogens for endocrine resistant Breast Cancer
ER+ breast cancer raises a significant diagnostic challenge since resistance invariably develops to the current endocrine therapies. 70% of breast cancers are ER+, which results from the overexpression of estrogen receptor. ER mediates strong anti-inflammatory signaling in ER+ tissues. Once …
Page 1 of 2